A randomized, double-blind, placebo-controlled trial of metoclopramide for the treatment of Tourette's disorder

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 44, Issue 7, 2005, Pages 640-646

  Nicolson, Rob ^a,c   Craven Truss, Beth ^a   Smith, Judy ^a   McKinlay, B Duncan ^a   Castellanos, F Xavier ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b NEW YORK UNIVERSITY CHILD STUDY CENTER   (United States)

^c NONE   (Canada)

Author keywords

Dopamine antagonist; Metoclopramide; Tourette's disorder; Treatment

Indexed keywords

METOCLOPRAMIDE; PLACEBO;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DIARRHEA; DIZZINESS; DYSKINESIA; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GILLES DE LA TOURETTE SYNDROME; HEART FUNCTION; HUMAN; INCREASED APPETITE; MALE; MOOD DISORDER; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHOOL CHILD; SCORING SYSTEM; SEDATION; SIDE EFFECT; TIC; TITRIMETRY; TREATMENT OUTCOME; WEIGHT;

EID: 21044447399     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.chi.0000163279.39598.44     Document Type: Article

References (36)

1. Acosta MT, Castellanos FX (2004), Use of the "inverse neuroleptic" metoclopramide in Tourette syndrome: an open case series. J Child Adolesc Psychopharmacol 14:123-128
2. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, Risperidone Disruptive Behavior Study Group (2002), Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346
3. American Psychiatric Association (2000), Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV- TR). Washington, DC: American Psychiatric Association
4. Bruggeman R, van der Linden C, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA (2001), Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 62:50-56
5. Campbell M, Palij M (1985), Measurement of side effects, including tardive dyskinesia. Psychopharmacol Bull 21:1063-1082
6. Conners CK (1989), Manual for Conners Rating Scales. North Tonawanda, NY: Multi-Health Systems
7. Conners CK, Barkley RA (1985), Rating scales and checklists for child psychopharmacology. Psychopharmacol Bull 21:809-851
8. Desai AB, Doongaji DR, Satoskar RS (1983), Metoclopramide in Gilles de la Tourette's syndrome (a case report). J Postgrad Med 29:181-183
9. Deutch AY, Bourdelais AJ, Zahm DS (1993), The nucleus accumbens core and shell: accumbal compartments and their functional attributes. In: Limbic Motor Circuits and Neuropsychiatry, Kalivas PW, Barnes CD, eds. Boca Raton, FL: CRC Press, pp 45-89
10. Deutch AY, Lewis DA, Whitehead RE et al. (1996), Effects of D2 dopamine receptor antagonists on Fos protein expression in the striatal complex and entorhinal cortex of the nonhuman primate. Synapse 23:182-191
11. Gagliano A, Germano E, Pustorino G et al. (2004), Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 14:39-47
12. Ganzini L, Casey DE, Hoffman WF, McCall AL (1993), The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 153:1469-1475
13. Gilbert DL, Batterson JR, Sethuraman G, Sallee FR (2004), Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 43:206-214
14. Goodman WK, Price LH, Rasmussen SA et al. (1989), The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011
15. Haddad PM, Wieck A (2004), Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features and management. Drugs 64:2291-2314
16. Hasan EI, Amro BI, Arafat T, Badwan AA (2003), Assessment of a controlled release hydrophilic matrix formulation for metoclopramide HCl. Eur J Pharm Biopharm 55:339-344
17. Hiroi N, Graybiel AM (1996), Atypical and typical neuroleptic treatments induce distinct programs of transcription factor expression in the striatum. J Comp Neurol 374:70-83
18. Jankovic J (2001), Tourette's syndrome. N Engl J Med 345:1184-1192
19. Kaufman J, Birmaher B, Brent D et al. (1997), Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988
20. Leckman JF (2002), Tourette's syndrome. Lancet 360:1577-1586
21. Leckman JF, Riddle MA, Hardin MT et al. (1989), The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28:566-573
22. Margolese HC, Annable L, Dion Y (2002), Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. J Clin Psychiatry 63:1040-1044
23. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS (1976), Metoclopramide: a review of its pharmacological properties and clinical use. Drugs 12:81-131
24. Robertson GS, Matsumura H, Fibiger HC (1994), Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271:1058-1066
25. Robertson MM (2003), Diagnosing Tourette syndrome: is it a common disorder? J Psychosom Res 55:3-6
26. Sallee FR, Kurlan R, Goetz CG et al. (2000), Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 39:292-299
27. Sandor P (2003), Pharmacological management of tics in patients with TS. J Psychosom Res 55:41-48
28. Scahill L, Leckman JF, Schults RT, Katsovich L, Peterson BS (2003), A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60:1130-1135
29. Shapiro E, Shapiro AK, Fulop GK et al. (1989), Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 46:722-730
30. Simpson GM, Angus JW (1970), A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19
31. Singer HS, Wendlandt JT (2001), Neurochemistry and synaptic transmission in Tourette syndrome. Adv Neurol 85:163-178
32. Smirnov AIU (1989), Use of metoclopramide (Cerucal) in Tourette syndrome. Zh Neuropatol Psikhiatr Im S S Korsakova 89:105-108
33. Stanley M, Lautin A, Rotrosen J, Gershon S, Kleinberg D (1980), Metoclopramide: antipsychotic efficacy of a drug lacking potency in receptor models. Psychopharmacology (Berl) 71:219-225
34. Tabachnick BG, Fidell LS (1996), Using Multivariate Statistics, 3rd ed. New York: Harper Collins
35. Voruganti L, Awad AG (2004), Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl) 171:121-132
36. Wudarsky M, Nicolson R, Hamburger SD et al. (1999), Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 9:239-245